As mentioned in the present manuscript, hosts with higher expression of MCM2 might be more susceptible to MDS‐type myeloid neoplasms while MCM2‐low hosts have a higher risk of developing AML or MPN when genetic mutations occur in hematopoietic stem cells. This evidence concerns the gene MCM2 and myeloproliferative disorder.